Severe Acute Respiratory Syndrome Clinical Trial
Severe acute respiratory syndrome (SARS) is a new threat to public health since November,
2002. The SARS is highly contagious and is believed to be transmitted by person-to-person
through droplet and direct contact. The patients present with fever, chills, cough, myalgia,
dyspnea, and diarrhea. The symptoms aggravate in the second week and nearly 40% of the
patients develop respiratory failure that requires assisted ventilation. The mortality rate
is reported as 6.5%-7%.
After several months, the world scientists found the etiology to be a new coronavirus not
belonging to the previous coronavirus group I, II and III. The new virus is called SARS
associated coronavirus (SARS-CoV).
Although the high morbidity and mortality of SARS occurred in adults, there was rare
mortality reported in the children. The report from Hong Kong pointed out that the symptoms
of SARS in younger children were milder and the clinical course was not as aggressive as in
adults. Therefore, the aim of the project is to design the experiment to see the differences
of immunological responses to SARS-CoV protein in healthy younger children, teenagers, and
adults. The investigators hope that the result could explain the reason for milder disease
in younger children and the immunological pathogenesis of SARS.
n/a
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04542915 -
COVID-19-Related Health and Practices Among Dental Hygienists
|
||
| Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
| Recruiting |
NCT04480333 -
Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831
|
Phase 1 | |
| Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 | |
| Withdrawn |
NCT04838847 -
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
|
Phase 3 | |
| Not yet recruiting |
NCT04386070 -
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
|
Phase 3 | |
| Withdrawn |
NCT00073086 -
Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)
|
N/A | |
| Active, not recruiting |
NCT04527432 -
COVID-19 Health Professional Impact Study
|
N/A | |
| Completed |
NCT00215826 -
Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers
|
Phase 2 | |
| Completed |
NCT04366934 -
Study of the Pathogenesis of Olfactory Disorders in COVID-19
|
||
| Completed |
NCT04402060 -
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04376684 -
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
|
Phase 2 | |
| Completed |
NCT04395144 -
COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss
|
N/A | |
| Completed |
NCT04357730 -
Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection
|
Phase 2 | |
| Completed |
NCT04425213 -
Obesity and Mortality of Critically Ill Patients With COVID-19
|
||
| Completed |
NCT04425863 -
Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19
|
||
| Completed |
NCT06287554 -
Effect of Early Implementation of Prone Positioning
|
||
| Completed |
NCT04328129 -
Household Transmission Investigation Study for COVID-19 in Tropical Regions
|
N/A | |
| Completed |
NCT04602351 -
Communication in ICU During COVID-19
|
||
| Completed |
NCT03225807 -
Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure
|